The joint evaluation of the legislation on medicines for children and rare diseases (medicines for special populations) is now underway. This is an important step in the process of assessing the impact of EU rules for these medical areas. One of the goals of the evaluation is to estimate the efficiency and effectiveness of the two regulations, particularly in the light of the latest pharmaceutical developments; including the impact of the incentives for research, development and marketing of children's and orphan medicines. Interested parties, especially health professionals and citizens, are invited to share their views via this public consultation until 4 January 2019 to help to shape the EU policy on medicines for children and rare diseases.

For more information:

• EU action on Medicines for children 
• EU action on Orphan medicinal products